Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields

被引:3
|
作者
Lan, Yue [1 ,2 ,3 ,4 ]
Zhang, Shaomin [2 ,3 ,4 ]
Pan, Yun [5 ]
Wang, Minmin [2 ,3 ,4 ,6 ]
Chen, Guangdi [1 ]
机构
[1] Zhejiang Univ, Dept Publ Hlth, Sch Med, Hangzhou 310027, Peoples R China
[2] Zhejiang Univ, Dept Biomed Engn, Qiushi Acad Adv Studies, Hangzhou 310027, Peoples R China
[3] Zhejiang Univ, Key Lab Biomed Engn, Minist Educ, Hangzhou 310027, Peoples R China
[4] Zhejiang Univ, Zhejiang Prov Key Lab Cardiocerebral Vasc Detect T, Hangzhou 310027, Peoples R China
[5] Zhejiang Univ, Coll Informat Sci & Elect Engn, Hangzhou 310027, Peoples R China
[6] Zhejiang Univ, Binjiang Inst, Hangzhou 310027, Peoples R China
基金
国家重点研发计划;
关键词
tumor treating fields; mechanism of action; anti-tumor immunity; immunotherapy; TUMOR-TREATING FIELDS; RANDOMIZED PHASE-III; GLIOBLASTOMA; TEMOZOLOMIDE; THERAPY; IMMUNOSURVEILLANCE; CHEMOTHERAPY; NOVOTTF-100A; SURVIVAL; TRIAL;
D O I
10.3390/cancers15235642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Although conventional and emerging treatment modalities have improved the survival outcomes of cancer patients to some extent, the prognosis for solid tumors remains notably grim. Tumor treating fields, as a novel approach for cancer therapy, have shown promising effects as both a monotherapy and in combination with chemotherapy. However, the underlying mechanisms through which TTFields exert their anticancer effects remain incompletely understood. In recent years, many researchers have suggested that inducing anti-tumor immune responses may be one of the key mechanisms of the anticancer activity of TTFields. Several clinical trials are currently exploring the combination of TTFields with tumor immunotherapy and have achieved positive results. This article reviews the research progress on the mechanisms of TTFields-induced anti-tumor immune responses and discusses their clinical significance. The objective is to offer a streamlined and precise summary to facilitate the future exploration and advancement of TTFields.Abstract Tumor treating fields (TTFields), a biophysical therapy technology that uses alternating electric fields to inhibit tumor proliferation, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of newly diagnosed or recurrent glioblastomas (GBM) and malignant pleural mesotheliomas (MPM). Clinical trials have confirmed that TTFields are effective in slowing the tumor growth and prolonging patient survival. In recent years, many researchers have found that TTFields can induce anti-tumor immune responses, and their main mechanisms include upregulating the infiltration ratio and function of immune cells, inducing the immunogenic cell death of tumor cells, modulating immune-related signaling pathways, and upregulating the expression of immune checkpoints. Treatment regimens combining TTFields with tumor immunotherapy are emerging as a promising therapeutic approach in clinical practice. Given the increasing number of recently published studies on this topic, we provide an updated review of the mechanisms and clinical implications of TTFields in inducing anti-tumor immune responses. This review not only has important reference value for an in-depth study of the anticancer mechanism of TTFields but also provides insights into the future clinical application of TTFields.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Endogenous Retrovirus Activation as a Key Mechanism o Anti-Tumor Immune Response in Radiotherapy
    Lee, Andrew K.
    Pan, Dong
    Bao, Xuhui
    Hu, Mengjie
    Li, Fang
    Li, Chuan-Yuan
    RADIATION RESEARCH, 2020, 193 (04) : 305 - 317
  • [32] INDUCTION OF ANTI-TUMOR IMMUNITY BY TUMOR TREATING FIELDS (TTFIELDS) IN GLIOBLASTOMA
    Chen, Dongjiang
    Le, Son
    Hutchinson, Tarun
    Jin, Dan
    Sebastian, Mathew
    Liu, Tianyi
    Ghinaseddin, Ashley
    Rahman, Maryam
    Tran, David
    NEURO-ONCOLOGY, 2021, 23 : 100 - 100
  • [33] B cell regulation of anti-tumor immune response
    Zhang, Yu
    Morgan, Richard
    Podack, Eckhard R.
    Rosenblatt, Joseph
    IMMUNOLOGIC RESEARCH, 2013, 57 (1-3) : 115 - 124
  • [34] B cell regulation of anti-tumor immune response
    Yu Zhang
    Richard Morgan
    Eckhard R. Podack
    Joseph Rosenblatt
    Immunologic Research, 2013, 57 : 115 - 124
  • [35] Intratumoral dendritic cells in the anti-tumor immune response
    Yang Liu
    Xuetao Cao
    Cellular & Molecular Immunology, 2015, 12 : 387 - 390
  • [36] Restraint stress and anti-tumor immune response in mice
    Posevitz, V
    Vizler, C
    Benyhe, S
    Duda, E
    Borsodi, A
    ACTA BIOLOGICA HUNGARICA, 2003, 54 (02): : 167 - 176
  • [37] Intratumoral dendritic cells in the anti-tumor immune response
    Liu, Yang
    Cao, Xuetao
    CELLULAR & MOLECULAR IMMUNOLOGY, 2015, 12 (04) : 387 - 390
  • [38] Restraint Stress and Anti-Tumor Immune Response in Mice
    V. P. Osevitz
    C. Vizler
    S. Benyhe
    E. Duda
    Anna Borsodi
    Acta Biologica Hungarica, 2003, 54 : 167 - 176
  • [39] ANTI-TUMOR IMMUNE RESPONSE OF ONCOMAGNETIC MONOTHERAPY IN GLIOBLASTOMA
    Pandey, Arvind
    Hambarde, Shashank
    Baskin, David S.
    Helekar, Santosh A.
    NEURO-ONCOLOGY, 2023, 25
  • [40] Anti-tumor immune response after photodynamic therapy
    Mroz, Pawel
    Castano, Ana P.
    Wu, Mei X.
    Kung, Andrew L.
    Hamblin, Michael R.
    12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION: PHOTODYNAMIC THERAPY: BACK TO THE FUTURE, 2009, 7380